The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic. The impact of the pandemic on European health systems and more broadly on society, will make it necessary for sponsors to adjust how they manage clinical trials and the people who participate in these trials. It is an extensive guidance to sponsors in response to coronavirus pandemic.
How to Manage Clinical Trials during COVID-19 – Massive Bio
Massive Bio has onboarded over 160,000+ cancer patients to find their clinical trial
